Stockwatch: Signs of uncertainty
This article was originally published in Scrip
Executive Summary
Just how good is the market in untangling involved technical developments and complex business machinations among pharmaceutical companies? At first glance, not so good, at least in the evolving field of hepatitis C treatments.